Zhengye Biotechnology Holding Limited ZYBT
- Market cap
- $40.1M
- P/E
- —
Follow ZYBT
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | 1.11 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | — | 14.30 |
High Price
|
|||
| — | — | — | — | — | — | — | 278 | 277 | 269 |
Employees
|
|||
| — | — | — | — | — | — | — | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | 29 | 26 | 17 |
Revenue
|
|||
| — | — | — | — | — | — | — | 61.35% | 48.99% | 20.51% |
Gross Margin
|
|||
| — | — | — | — | — | — | — | 6 | 2 | (10) |
EBT
|
|||
| — | — | — | — | — | — | — | 20.67% | 7.73% | (61.78%) |
EBT Margin
|
|||
| — | — | — | — | — | — | — | 5 | 2 | (12) |
Net Income
|
|||
| — | — | — | — | — | — | — | 3 | 3 | 4 |
Depreciation
|
|||
| — | — | — | — | — | — | — | 0.64 | 0.56 | 0.35 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | 0.11 | 0.03 | (0.21) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | 0.15 | 0.12 | 0.04 |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | (0.03) | (0.08) | (0.04) |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | 0.11 | 0.04 | 0.00 |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | 1.02 | 1.06 | 0.93 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | 46 | 46 | 47 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
PB Ratio
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
EV/Sales
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.61 |
EV/FCF
|
|||
| — | — | — | — | — | — | — | 7 | 6 | 2 |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | (1) | (4) | (2) |
Capex
|
|||
| — | — | — | — | — | — | — | 5 | 2 | 0 |
FCF
|
|||
| — | — | — | — | — | — | — | 8 | 6 | 2 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | 12 | 12 | 11 |
Total Debt
|
|||
| — | — | — | — | — | — | — | 8 | 9 | 3 |
Net Debt
|
|||
| — | — | — | — | — | — | — | 47 | 48 | 44 |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | 0.00% | 2.27% | (15.36%) |
ROA
|
|||
| — | — | — | — | — | — | — | 7.02% | 2.45% | (13.38%) |
ROIC
|
|||
| — | — | — | — | — | — | — | 0.00% | 3.26% | (21.66%) |
ROE
|
|||
Zhengye Biotechnology Holding Limited peers in Drug Manufacturers Specialty & Generic
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| IXHL Incannex Healthcare Inc. | $40.7M | 0.0× | Compare |
| SCYX SCYNEXIS, Inc. | $45.0M | 0.0× | Compare |
| RMTI Rockwell Medical, Inc. | $34.5M | 0.0× | Compare |
| CPHI China Pharma Holdings, Inc. | $31.8M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| TLPH Talphera, Inc. | $60.7M | 0.0× | Compare |
| INCR InterCure Ltd. | $62.3M | 9.8× | Compare |
| AYTU Aytu BioPharma, Inc. | $25.1M | 0.0× | Compare |
| TXMD TherapeuticsMD, Inc. | $24.7M | 0.0× | Compare |
Zhengye Biotechnology Holding Limited (ZYBT) key facts
- Zhengye Biotechnology Holding Limited (ZYBT) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
- Zhengye Biotechnology Holding Limited’s revenue for fiscal 2025 (year ended December 2025) was $16.6 million, down 34.8% from fiscal 2024.
- Zhengye Biotechnology Holding Limited reported a net loss of $11.9 million, or a loss of $0.21 per share, for fiscal 2025.
- As of September 25, 2026, ZYBT traded at $1.31, a market capitalization of $40.1 million.
- Return on equity was −21.7% and debt-to-equity 0.24.
Zhengye Biotechnology Holding Limited (ZYBT) Latest News
4 Jun
Zhengye Biotechnology Holding Limited received a Nasdaq notification for failing to meet the minimum $1 bid price requirement, triggering a 180-day compliance period to regain eligibility or face potential delisting proceedings. Nasdaq minimum bid price deficiency notice creates delisting risk that can pressure stock price and limit capital access.
28 Apr
Zhengye Biotechnology Holding Limited announced its Fiscal Year 2025 financial results. Fiscal year financial results announcements significantly influence stock prices, investor sentiment, and assessments of company performance.
6 Apr
Zhengye Biotechnology Holding Limited announces implementation of dual-class share structure. Dual-class share structure grants insiders superior voting control, significantly impacting governance, investor sentiment, and long-term strategic flexibility.
10 Feb
Zhengye Biotechnology Holding Limited has released its 2026 Chairman’s Letter to Shareholders, outlining the company's strategic vision and operational goals for the upcoming years. The letter emphasizes commitment to innovation, market expansion, and enhancing shareholder value. Key initiatives and performance metrics are highlighted, showcasing the company's growth trajectory and future plans. The letter outlines significant strategic initiatives that could notably influence the company's future performance and investor sentiment.
14 Sep
Zhengye Biotechnology Holding Limited (ZYBT) reported a return on equity (ROE) of 3.8%, raising concerns among investors regarding its financial performance. A low ROE may indicate inefficiencies in generating profits from shareholders' equity, potentially affecting investor confidence. Comparisons with industry peers suggest that ZYBT's ROE is below average, prompting questions about its operational effectiveness and future growth prospects. Analysts emphasize the importance of evaluating ROE alongside other financial metrics to gain a comprehensive understanding of the company's performance. A low ROE may affect investor sentiment and financial performance, but it is not expected to fundamentally alter the company's trajectory.
3 Jul
Zhengye Biotechnology Holding Limited reported its financial results for fiscal year 2024, highlighting significant growth in revenue and net income compared to the previous year. The company attributed this success to increased demand for its biotechnology products and successful market expansion strategies. Management expressed optimism about future growth prospects and plans to invest in research and development to enhance product offerings. Overall, the results reflect a positive trajectory for the company in the competitive biotechnology sector. The financial results indicate significant growth and strategic plans that could alter the company's trajectory and investor sentiment.
23 May
Zhengye Biotechnology Holding Limited has received a notice from NASDAQ regarding the late filing of its Form 20-F. The company is required to submit the form, which is an annual report for foreign companies, to remain compliant with NASDAQ listing rules. The notice indicates that the company is at risk of being delisted if it fails to file the necessary documentation in a timely manner. Late filing of regulatory documents can affect investor confidence and market perception.
14 Jan
Zhengye Biotechnology Holding Limited announced the full exercise of the underwriters’ over-allotment option in connection with its recent public offering. This move allows the company to raise additional capital, enhancing its financial position and supporting future growth initiatives. The underwriters exercised the option to purchase an additional number of shares, indicating strong demand for the offering. The full exercise of the over-allotment option signifies strong market demand and provides additional capital that can significantly impact future growth and investor sentiment.
8 Jan
Zhengye Biotechnology Holding Limited has successfully closed its initial public offering (IPO), raising significant capital to support its growth and expansion strategies. The IPO attracted considerable investor interest, reflecting confidence in the company's potential within the biotechnology sector. The funds raised will be utilized for research and development, operational enhancements, and potential market expansion initiatives. The successful IPO is expected to provide substantial capital for strategic growth initiatives, significantly impacting the company's future performance.
6 Jan
Zhengye Biotechnology Holding Limited has announced the pricing of its initial public offering (IPO), setting the price at $5.00 per share. The company aims to raise approximately $10 million through the offering, which is expected to close on a specified date. The proceeds will be utilized for research and development, working capital, and other general corporate purposes. The IPO is seen as a significant step for Zhengye Biotechnology as it seeks to expand its presence in the biotechnology sector. The IPO represents a major strategic move that could significantly enhance the company's financial position and market presence.